Estrogen signaling is active in cartilaginous tumors: Implications for antiestrogen therapy as treatment option of metastasized or irresectable chondrosarcoma

Clinical Cancer Research

Volumn 11, Issue 22, 2005, Pages 8028-8035

  Cleton Jansen, Anne Marie ^a   Van Beerendonk, Hetty M ^a   Baelde, Hans J ^a   Bovée, Judith V G M ^a   Karperien, Marcel ^a   Hogendoorn, Pancras C W ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTENEDIONE; ANTIESTROGEN; AROMATASE; ESTROGEN; ESTROGEN RECEPTOR; EXEMESTANE; MESSENGER RNA; TRITIUM OXIDE;

ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CARTILAGE CELL; CARTILAGE MATRIX; CELL DIFFERENTIATION; CELL PROLIFERATION; CHONDROSARCOMA; CULTURE MEDIUM; DOSE RESPONSE; DRUG RESPONSE; ENZYME ACTIVITY; ENZYME ASSAY; EPIPHYSIS; ESTROGEN SYNTHESIS; FEMALE; GROWTH PLATE; HUMAN; HUMAN CELL; HUMAN TISSUE; LONG BONE; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TRITIATED WATER RELEASE ASSAY;

ADULT; AGED; ANDROSTADIENES; ANDROSTENEDIONE; AROMATASE; AROMATASE INHIBITORS; BONE NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CHONDROSARCOMA; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTROGEN ANTAGONISTS; ESTROGENS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; RECEPTORS, ESTROGEN; RNA, MESSENGER; SIGNAL TRANSDUCTION;

EID: 28144449722     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-1253     Document Type: Article

References (38)

1. Bertoni F, Bacchini P, Hogendoorn PCW. Chondrosarcoma, In: Fletcher CDM, Unni KK, Mertens F, editors. World Health Organization classification of tumours. Pathology and genetics of tumours of soft tissue and bone. Lyon (France): IARC Press; 2002. p. 247-51.
2. Evans HL, Ayala AG, Romsdahl MM. Prognostic factors in chondrosarcoma of bone. A clinicopathologic analysis with emphasis on histologic grading. Cancer 1977;40:818-31.
3. Lee FY, Mankin HJ, Fondren G, et al. Chondrosarcoma of bone: an assessment of outcome. J Bone Joint Surg Am 1999;81:326-38.
4. Van der Eerden BCJ, Karperien M, Wit JM. The estrogen receptor in the growth plate: implications for pubertal growth. J Pediatr Endocrinol Metab 2001;14 Suppl 6:1527-33.
5. Grumbach MM. Estrogen, bone, growth and sex: a sea change in conventional wisdom. J Pediatr Endocrinol Metab 2000;13 Suppl 6:1439-55.
6. Mueller MD, Vigne JL, Minchenko A, Lebovic DI, Leitman DC, Taylor RN. Regulation of vascular endothelial growth factor (VEGF) gene transcription by estrogen receptors α and β. Proc Natl Acad Sci U S A 2000;97:10972-7.
7. Elkin M, Orgel A, Kleinman HK. An angiogenic switch in breast cancer involves estrogen and soluble vascular endothelial growth factor receptor1. J Natl Cancer Inst 2004;96:875-8.
8. Geirnaerdt MJ, Hogendoorn PCW, Bloem JL, Taminiau AHM, Van derWoude HJ. Cartilaginous tumors: fast contrast-enhanced MR imaging. Radiology 2000;214:539-46.
9. Elkin M, Cohen I, Zcharia E, et al. Regulation of heparanase gene expression by estrogen in breast cancer. Cancer Res 2003;63:8821-6.
10. Simpson ER. Sources of estrogen and their importance. J Steroid Biochem Mol Biol 2003;86:225-30.
11. Bulun SE, Simpson ER. Regulation of aromatase expression in human tissues. Breast Cancer Res Treat 1994;30:19-29.
12. Tang S, Han H, Bajic VB. ERGDB: estrogen responsive genes database. Nucleic Acids Res 2004;32 Database issue:D533-6.
13. Santen RJ, Harvey HA. Use of aromatase inhibitors in breast carcinoma. Endocr Relat Cancer 1999;6:75-92.
14. Osborne CK, Zhao H, Fuqua SA. Selective estrogen receptor modulators: structure, function, and clinical use. J Clin Oncol 2000;18:3172-86.
15. Simpson ER, Clyne C, Rubin G, et al. Aromatase-a brief overview. Annu Rev Physiol 2002;64:93-127.
16. Bovée JVMG, Van den Broek LJCM, De Boer WI, Hogendoorn PCW. Expression of growth factors and their receptors in adamantinoma of long bones and the implications for its histogenesis. J Pathol 1998;184:24-30.
17. Grill HJ, Manz B, Belovsky O, Pollow K. Criteria for the establishment of a double-labeling assay for simultaneous determination of estrogen and progesterone receptors. Oncology 1984;41:25-32.
18. Van der Eerden BCJ, Van DV, Lowik CW, Wit JM, Karperien M. Sex steroid metabolism in the tibial growth plate of the rat. Endocrinology 2002;143:4048-55.
19. KunisadaT, Miyazaki M, Mihara K, et al. A new human chondrosarcoma cell line (OUMS-27) that maintains chondrocytic differentiation. Int J Cancer 1998; 77:854-9.
20. Egerbacher M, Helmreich M, Rossmanith W, Haeusler G. Estrogen receptor-α and estrogen receptor-β are present in the human growth plate in childhood and adolescence, in identical distribution. Horm Res 2002;58:99-103.
21. Rodd C, Jourdain N, Alini M. Action of estradiol on epiphyseal growth plate chondrocytes. Calcif Tissue Int 2004;75:214-24.
22. Van der Eerden BCJ, Emons J, Ahmed S, et al. Evidence for genomic and nongenomic actions of estrogen in growth plate regulation in female and male rats at the onset of sexual maturation. J Endocrinol 2002; 175:277-88.
23. Odink AE, van Asperen CJ, Vandenbroucke JP, Cleton-Jansen AM, Hogendoorn PC. An association between cartilaginous tumours and breast cancer in the national pathology registration in The Netherlands points towards a possible genetic trait. J Pathol 2001; 193:190-2.
24. Cleton-Jansen AM, Timmerman MC, Van de Vijver MJ, et al. A distinct phenotype characterizes tumors from a putative genetic trait involving chondrosarcoma and breast cancer occurring in the same patient. Lab Invest 2004;84:191-202.
25. Brueggemeier RW, Richards JA, Petrel TA. Aromatase and cyclooxygenases: enzymes in breast cancer. J Steroid Biochem Mol Biol 2003;86:501-7.
26. Tonelli F, Ficari F, Valanzano R, Brandi ML. Treatment of desmoids and mesenteric fibromatosis in familial adenomatous polyposis with raloxifene. Tumori 2003; 89:391-6.
27. Rabbani SA, Khalili P, Arakelian A, Pizzi H, Chen G, Goltzman D. Regulation of parathyroid hormone-related peptide by estradiol: effect on tumor growth and metastasis in vitro and in vivo. Endocrinology 2005;146:2885-94.
28. Corvol MT, Carrascosa A, Tsagris L, Blanchard O, Rappaport R. Evidence for a direct in vitro action of sex steroids on rabbit cartilage cells during skeletal growth: influence of age and sex. Endocrinology 1987;120:1422-9.
29. van der Eerden BC, Karperien M, Wit JM. Systemic and local regulation of the growth plate. Endocr Rev 2003;24:782-801.
30. Paspaliaris V, Vargas SJ, Gillespie MT, et al. Oestrogen enhancement of the myometrial response to exogenous parathyroid hormone-related protein (PTHrP), and tissue localization of endogenous PTHrP and its mRNA in the virgin rat uterus. J Endocrinol 1992;134:415-25.
31. Rozeman LB, Hameetman L, Cleton-Jansen AM, Taminiau AHM, Hogendoorn PCW, Bovée JVMG. Absence of IHH and retention of PTHrP signalling in enchondromas and central chondrosarcomas. J Pathol 2005;205:476-82.
32. Wickman S, Sipila I, Ankarberg-Lindgren C, Norjavaara E, Dunkel L. A specific aromatase inhibitor and potential increase in adult height in boys with delayed puberty: a randomised controlled trial. Lancet 2001;357:1743-8.
33. Brodie A. Aromatase inhibitors in breast cancer. Trends Endocrinol Metab 2002;13:61-5.
34. Miyaji T, Nakase T, Onuma E, et al. Monoclonal antibody to parathyroid hormone-related protein induces differentiation and apoptosis of chondrosarcoma cells. Cancer Lett 2003;199:147-55.
35. Bovée JVMG, Van den Broek LJCM, Cleton-Jansen AM, Hogendoorn PCW. Up-regulation of PTHrP and Bcl-2 expression characterizes the progression of osteochondroma towards peripheral chondrosarcoma and is a late event in central chondrosarcoma. Lab Invest 2000;80:1925-33.
36. Hameetman L, Kok P, Eilers PHC, Cleton-Jansen AM, Hogendoorn PCW, Bovée JVMG. Distinguishing osteochondromas from grade I secondary peripheral chondrosarcomas: influence of patient gender and age on the use of Bcl-2 and PTHrP immunohistochemistry Virchows Arch 2005;446:430-7.
37. Rozeman LB, Hogendoorn PCW, Bovée JVMG. Diagnosis and prognosis of chondrosarcoma of bone. Expert Rev Mol Diagn 2002;2:461-72.
38. Bovée JVMG, Cleton-Jansen AM, Wuyts W, et al. EXT-mutation analysis and loss of heterozygosity in sporadic and hereditary osteochondromas and secondary chondrosarcomas. Am J Hum Genet 1999;65:689-98.